HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

European animal test ban

This article was originally published in The Rose Sheet

Executive Summary

Proposed legislation to ban sale of new cosmetic products and ingredients tested on animals in EU if validated alternative exists has moved to conciliation phase after Oct. 7 meeting in which European Parliament and EU Council of Ministers were unable to find common ground. Tentative Nov. 6 meeting will be deadline for developing compromise text agreement between Parliament, council and European Commission. Draft expected to address how to produce alternatives to animal testing, means by which those tests can be validated and "on whose authority and what message would be approved for validating." In Parliament's second reading of the Seventh Amendment of the Cosmetics Directive June 11, legislators voted in favor of including a marketing ban in the directive (1"The Rose Sheet" June 17, 2002, p. 3)...

Latest Headlines
See All
UsernamePublicRestriction

Register

RS010665

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel